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Study Objectives: To investigate behavioral aspects and quality of life in children and adolescents with type 1 narcolepsy (NT1).
Methods: We performed a case-control study comparing 29 patients with NT1 versus sex- and age-matched patients with idiopathic epilepsy (n = 39) and 
healthy controls (n = 39). Behavior and quality of life were evaluated by self-administered questionnaires (Child Behavior Checklist, Pediatric Quality of 
Life Inventory). Patient groups were contrasted and scale results were correlated with clinical and polysomnographic parameters, and cerebrospinal fluid 
hypocretin-1 levels.
Results: Young patients with NT1 showed increased internalizing problems associated with aggressive behavior. Emotional profile in patients with NT1 
positively correlated with age at onset, diagnostic delay, and subjective sleepiness, whereas treatment and disease duration were associated with fewer 
behavioral problems (attention problems, aggressive behavior, and attention deficit/hyperactivity disorder). Psychosocial health domains of pediatric NT1 
were worse than in healthy controls, whereas the physical health domains were comparable.
Conclusions: Young NT1 patients show a discrete pattern of altered behavioral, thought, and mood profile in comparison with healthy controls and with 
idiopathic epilepsy patients thus suggesting a direct link with sleepiness. Further studies investigating behavior in patients with idiopathic hypersomnia or 
type 2 narcolepsy are needed to disentangle the role of REM sleep dysfunction and hypocretin deficiency in psychiatric disorders. Symptoms of withdrawal, 
depression, somatic complaints, thought problems, and aggressiveness were common, NT1 children perceived lower school competencies than healthy 
children, and their parents also reported worse psychosocial health.Our data suggest that early effective treatment and disease self-awareness should be 
promoted in NT1 children for their positive effect on behavior and psychosocial health.
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INTRODUCTION
Type 1 narcolepsy (NT1) is a chronic central disorder of hy-
persomnolence characterized by excessive daytime sleepiness 
(EDS), cataplexy, sleep paralyses, hypnagogic hallucinations, 
and disrupted nocturnal sleep.1 NT1 is linked to hypothalamic 
hypocretin deficiency of possible autoimmune origin as sug-
gested by the genetic predisposition of human leukocyte an-
tigen (HLA) alleles combined with triggering environmental 
factors.1,2 NT1 greatly affects patients’ quality of life (QoL) in 
a homogeneous way across countries, independently from cul-
tural and geographic provenience.3
In children and adolescents, NT1 displays a peculiar phe-
notype that contributes to frequent misdiagnosis, and to the 
remarkable diagnostic delay.4–11 Young patients can mani-
fest EDS with sleep attacks as well as with long periods of 
daytime and nighttime sleep, or with hyperactive behavior 
and irritability that may resemble neurodevelopmental 
disturbances.12,13 Young NT1 patients often experience a 
widespread impairment in their education and social rela-
tionships, and may suffer from neuropsychiatric disorders 
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Significance
Psychosocial profile was tested for the first time in young patients with Narcolepsy type 1 (NT1) in comparison with patients with Idiopathic Epilepsy (IE) 
and healthy controls. NT1 patients showed more psychological and behavioral problems that IE and control subjects, with a hierarchical order for the 
externalizing aspects (NT1 > IE > controls) and a peculiar profile in the internalizing features (NT1 > IE = controls). The psychological and behavioral 
aspects negatively influenced quality of life in NT1 patients. Pharmacological treatment of NT1 was associated with a better profile in the attention, 
aggressiveness, hyperactivity, and oppositional defiant areas. Further longitudinal studies including psychological and pharmacological interventions are 
warranted. Improving the psychosocial impairment in NT1 young patients could contribute to prevent major psychiatric comorbidities.
encompassing anxiety, depressive mood, psychotic symp-
toms, and attention deficit hyperactivity disorder (ADHD), as 
reported in adults.13–20 Both the large overlap between NT1 
and psychological problems and the possible involvement of 
the hypocretinergic system in psychiatric disorders raises 
the question whether the multifaceted psychological picture 
of childhood NT1 has to be considered and treated as an in-
trinsic dysfunction, reactive to NT1, or as a discrete real psy-
chiatric comorbidity.21,22
Psychiatric comorbidity in young NT1 was mostly described 
in case reports or anecdotally reported as intrinsic suscepti-
bility.23–31 Few studies used standardized tests to investigate 
different areas of psychosocial functioning, including social 
behavior, emotional and conduct problems, depressive mood, 
competences and behavioral problems, ADHD, schizophrenia, 
autism symptoms, and poor QoL outcomes.13,32–37 However, 
most studies were performed in small and heterogeneous NT1 
groups in parallel with other patient groups, or thorough un-
controlled designs including a mixture of patients with narco-
lepsy with and without cataplexy.13,32–37
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The aim of this study was to investigate behavioral aspects 
and QoL in young NT1 patients versus age- and sex- matched 
nonsleepy patients with epilepsy and healthy controls, using 
the Child Behavior Checklist (CBCL) and the Pediatric Quality 
of Life Inventory (PedsQL).
METHODS
Patients
Twenty-nine children and adolescents (age range 7–16 y) with 
a diagnosis of NT1 were recruited at the Outpatient Clinic for 
Narcolepsy of the Department of Biomedical and Neuromotor 
Sciences of the University of Bologna.1 Results of both 48 h 
polysomnographic continuous recording and Multiple Sleep 
Latency Test (MSLT) were available for all patients, whereas 
cerebrospinal fluid hypocretin-1 (CSF HCRT-1) levels were 
available only for 17 of 29 patients due to the parents’ re-
fusal to perform lumbar puncture. In all patients, brain mag-
netic resonance imaging (MRI) was normal. Patients were 
HLA-DQB1*06:02 positive, excluding a girl with proved CSF 
HCRT-1 deficiency. At study inclusion, patients completed the 
Pediatric Daytime Sleepiness Scale (PDSS).38
The parallel patients group consisted of 39 age- and sex-
matched children and adolescents (age range, 7–15 y) with id-
iopathic epilepsies (IE) according to international diagnostic 
criteria, followed at the Department of Woman and Child 
Health, University of Padua. Inclusion criteria required ab-
sence of sleep disorders complaints (including EDS) at clinical 
interview, and normal neurological examination and brain 
MRI.39
The healthy control group consisted of 39 age- and sex-
matched healthy children and adolescents (age range, 6–18 y) 
without complaints related to sleep disorders (including EDS). 
The control group was recruited among students attending 
three local schools during the academic year. After an infor-
mative interview, parents had a letter describing the research 
project, providing details of the test methods, and requesting 
that they sign a form to authorize the participation in compli-
ance with current legislation on privacy. The same question-
naires as those administered to the cases were anonymously 
administered in class during normal school hours.
The study was approved by the internal review board of all 
the institutes.
Questionnaires
NT1 patients and controls were investigated for both behav-
ioral (CBCL) and QoL (PedsQL) aspects, whereas the IE group 
served as pathological control group to compare the disease 
effect on behavioral domains.
Child Behavior Checklist 6–18
The CBCL 6–18, completed by parents, addresses skills and 
problems in patients aged 6 to 18 y and provides a picture of 
their social, emotional, and behavioral profile, divided in two 
parts.40–42 The first refers to the Competence and adaptive scales 
(daily activities, social interaction, and school performance), 
and the second to emotional and behavioral problems with 
eight different Syndrome scales: five of the aforementioned 
scales are further grouped into higher internalizing (anxious/
depressed, depressed-withdrawn, and somatic complaints) and 
externalizing (rule-breaking, and aggressive behavior) scales; 
the Total Problems scale comprised all 113 items. The six Di-
agnostic Statistical Manual (DSM)-Oriented scales consistent 
with DSM diagnostic categories completed the CBCL 2001 
version: affective disorder, anxiety disorder, somatic disorder, 
ADHD, oppositional defiant disorder (ODD), and conduct dis-
order (CD).43
Pediatric Quality of Life Inventory (PedsQL)
The PedsQL™ 4.0, copyright 1998 JW Varni, PhD All 
rights reserved, Generic Core Scales, Italian version is com-
posed of a patient self-report form and of a parent-proxy 
report form. PedsQL consists of 23 items addressing 4 
core domains: physical, emotional, social, and school func-
tioning.44,45 PedsQL is summarized into the following two 
measures: physical health summary score and psychosocial 
health summary score.
Statistical Analyses
Categorical and continuous data were reported as frequencies 
or mean (SD) for each group. CBCL raw scores were trans-
formed into T-scores to allow comparisons. CBCL results 
have been contrasted between the three groups with Kruskall-
Wallis analysis of variance followed by post hoc comparisons 
among groups with Mann-Whitney U test for continuous 
variables, and with chi-square tests for categorical variables. 
A subanalysis was also performed to compare treated versus 
untreated NT1 patients with Mann-Whitney U test.
Pearson correlation coefficient analyses were used to ad-
dress the relations between CBCL and PedsQL scores in NT1 
and control subjects, and between CBCL scores and clinical 
and polysomnographic data in NT1 and IE subjects.
A value of P ≤ 0.05 was considered statistically significant.
RESULTS
Participants’ Characteristics
At study inclusion, NT1 patients (55% males) had a mean age 
of 11.52 (2.89) y (range 7–16). NT1 patients reported EDS and 
cataplexy (100%), hypnagogic hallucinations (45%), sleep 
paralyses (28%), disturbed nocturnal sleep (79%), automatic 
behaviors (45%), and relevant weight gain (79%) occurring 
closely after NT1 symptoms onset. The mean PDSS score was 
15.24 (4.66). The mean age at onset of first symptom (either 
sleepiness or cataplexy) was 8.90 (2.35) y, and the mean dis-
ease duration was approximately 2.8 (2.95) y. The mean age 
at diagnosis was 10.45 (2.43) y, with a mean diagnostic delay 
of 1.55 (2.13) y. The mean number of schooling years was 
6.66 (2.74).
MSLT showed a mean sleep latency of 3.02 (2.09) min with 
4.41 (0.87) sleep onset rapid eye movement (REM) periods. 
Nocturnal polysomnography showed a mean total sleep time 
(TST) of 489.71 (72.64) min with a mean sleep latency of 5.89 
(3.97) min, sleep efficiency of 87.54 (14.24) %, and a mean 
REM sleep latency of 39.96 (56.92) min. During daytime poly-
somnography, patients showed a mean number of naps of 2.64 
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(1.75) with a mean TST of 117.11 (85.47) min. The mean CSF 
HCRT-1 levels were 29.93 (28.91) pg/mL.
Twenty-one patients (72%) were undergoing treatment 
(modafinil 69%, sodium oxybate 28%, and venlafaxine 7%) 
whereas eight patients (28%) were drug-naïve.
The IE group (51% males) mean age was 10.64 (2.02) y. The 
mean age at IE onset was 5.31 (1.54) y, and the mean disease 
duration was 5.36 (2.51) y. Twenty IE patients (51%) had local-
ization-related epilepsy and 19 (49%) idiopathic generalized 
epilepsy; 14 participants (36%) were receiving antiepileptic 
drug treatment, and 25 (64%) were drug-free. In the treated 
IE group of patients, 12 patients were under antiepileptic drug 
monotherapy (valproic acid, levetiracetam, carbamazepine, la-
motrigine, clobazam), and 2 patients received an antiepileptic 
drug politherapy (valproic acid + ethosuximide; lamotrigine + 
ethosuximide, respectively).
The control group mean age was 11.21 (3.44) y; there were 
20 males (51%) and 19 females (49%).
Behavior
Table 1 summarizes CBCL results as T-scores (mean, stan-
dard deviation) and as pathological findings in each group, ex-
pressed as the percentage of subject with pathological scores.
In Competence scales the three groups differed exclusively 
for social activities, with the NT1 patients having the lowest 
scores.
In withdrawn/depressed and somatic complaints areas, NT1 
patients had the highest scores and they more frequently had 
pathological scores versus IE and controls.
Both NT1 and IE groups showed higher scores than the 
control group for anxious/depressed, social and attention 
problems, without significant differences between NT1 and IE 
groups. NT1 patients had pathological scores than controls ex-
clusively in the anxious/depressed domain.
Thought and aggressive behavior scales showed the highest 
values in patients with NT1, intermediate in patients with IE, 
and lowest in healthy controls. Pathological values at thought 
scale were most prevalent among NT1 patients.
The three groups had comparable scores for rule-breaking 
behavior.
In total problem scales, the NT1 group showed higher inter-
nalizing and total problems scores as T-scores than the other 
two groups, and NT1 patients had more frequently pathological 
scores when compared with controls and IE patients. Finally, 
externalizing problems scores were highest in the NT1 group, 
intermediate in the IE group, and lowest in controls (Figure 1).
In DSM-oriented scales, the three groups differed for affec-
tive disorder, anxiety disorder, ADHD, ODD, and CD scores.
NT1 patients had significantly higher scores than IE patients 
who in turn differed from controls in the affective disorder 
scale, but only NT1 patients reached pathological score values 
at this scale.
Both the NT1 and IE groups showed higher scores in the 
anxiety disorder scale, and NT1 and IE patients had significant 
pathological scores compared to controls, without any differ-
ence between NT1 and IE.
ADHD and ODD scores were higher in both patients groups 
than in healthy controls, without differences in pathological 
Figure 1—Distribution of T-scores in Syndrome scales. Distribution of 
T-scores for NT1 (gray box), IE patients (dark gray box), and controls 
(black box) in Syndrome scales. In the box plot graph, box’s sides 
mark the first and third quartiles, the central line represents the median 
and the whiskers account for the maximum and minimum; outliers 
points lie outside the fences. The horizontal lines mark clinical/normal 
boundaries. CBCL, Child Behavior Checklist; IE, idiopathic epilepsies; 
NT1, narcolepsy type 1.
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Table 1—Child Behavioral Checklist T-scores and pathological scores (%) in type 1 narcolepsy patients, idiopathic epilepsy patients, and healthy control 
patients, with statistical comparison.
NT1 IE Controls T-Scores / Pathological %
T-Score T-Score T-Score K-W test/Chi Square Corrected P
Post hoc / Chi square
Mean SD Mean SD Mean SD 3 groups NT1 vs. IE NT1 vs. controls IE vs. controls
Competence and Adaptive Scales
Activities 34.93 8.42 35.59 7.46 37.95 8.80 0.28 5.76 0.52 0.13 0.28
Activities path (%) 63.00 66.70 53.80 0.49 9.90 0.75 0.46 0.24
Social 41.22 7.25 45.67 7.73 48.64 6.53 0.001 0.01 0.04  < 0.001 0.05
Social path (%) 33.30 7.70 2.60 0.001 0.02 0.008 0.001 0.30
School 47.10 5.70 47.41 6.70 49.82 4.74 0.131 2.62 0.67 0.05 0.13
School path (%) 3.40 12.80 0.00 0.04 0.82 0.17 0.24 0.02
Syndrome Scales
Anx/Dep 60.72 9.12 56.97 7.39 53.97 5.82 0.001 0.02 0.06  < 0.001 0.02
Anx/Dep path (%) 17.20 7.70 0.00 0.02 0.56 0.22 0.007 0.07
With/Dep 64.76 9.60 56.10 8.60 54.51 6.53  < 0.001  < 0.001  < 0.001  < 0.001 0.59
With/Dep path (%) 27.60 7.70 7.70 0.02 0.50 0.02 0.02 1.00
Som Compl 64.10 7.36 58.00 7.15 55.62 5.78  < 0.001  < 0.001 0.001  < 0.001 0.11
Som Compl path (%) 27.60 2.60 0.00  < 0.001  < 0.001 0.003  < 0.001 0.31
Soc Probl 58.86 9.17 56.64 5.87 53.97 5.48 0.006 0.12 0.64 0.007 0.005
Soc Probl path (%) 13.80 2.60 2.60 0.08 1.62 0.07 0.07 1.00
Th Probl 65.03 8.53 55.15 5.61 52.56 4.30  < 0.001  < 0.001  < 0.001  < 0.001 0.01
Th Probl path (%) 31.00 0.00 0.00  < 0.001  < 0.001  < 0.001  < 0.001 1.00
Att Probl 59.10 7.84 57.00 6.12 53.36 4.60 0.001 0.01 0.31 0.001 0.002
Att Probl path (%) 6.90 0.00 0.00 0.06 1.30 0.09 0.09 1.00
RBB 54.38 5.73 52.59 3.36 52.36 4.16 0.20 4.02 0.31 0.08 0.35
RBB path (%) 6.90 0.00 0.00 0.06 1.30 0.09 0.09 1.00
Aggr Behav 59.17 7.98 55.54 5.91 52.41 3.35  < 0.001  < 0.001 0.03  < 0.001 0.01
Aggr Behav path (%) 6.90 0.00 0.00 0.06 1.30 0.09 0.09 1.00
Total Problem Scales
Int Probl 64.76 8.94 54.64 11.28 49.36 11.34  < 0.001  < 0.001  < 0.001  < 0.001 0.05
Int Probl path (%) 51.70 23.10 15.40 0.003 0.06 0.01 0.001 0.38
Ext Probl 56.62 8.10 51.49 8.37 47.31 7.34  < 0.001  < 0.001 0.03  < 0.001 0.01
Ext Probl path (%) 17.20 7.70 2.60 0.09 1.92 0.22 0.03 0.30
Tot Probl 61.52 8.88 54.31 8.92 46.21 10.30  < 0.001  < 0.001 0.003  < 0.001 0.001
Tot Probl path (%) 41.40 12.80 5.10  < 0.001  < 0.001 0.007  < 0.001 0.23
DSM-Oriented Scales
Aff Dis 70.07 7.47 58.18 7.13 54.10 5.76  < 0.001  < 0.001  < 0.001  < 0.001 0.002
Aff Dis path (%) 57.70 2.60 0.00  < 0.001  < 0.001  < 0.001  < 0.001 0.31
Anx Dis 60.73 8.02 58.10 8.14 53.92 5.20 0.001 0.02 0.10  < 0.001 0.03
Anx Dis path (%) 23.10 15.40 0.00 0.01 0.22 0.43 0.002 0.01
Som Dis 59.88 8.96 57.21 7.50 55.56 6.34 0.08 1.66 0.21 0.02 0.27
Som Dis path (%) 7.70 5.10 5.10 0.88 17.78 0.67 0.67 1.00
ADHD 55.23 5.23 55.59 5.78 52.13 3.19 0.005 0.10 0.90 0.010 0.003
ADHD path (%) 0.00 2.60 0.00 0.43 8.62 0.41 1.00 0.31
ODD 57.23 5.96 55.49 6.18 52.44 3.18 0.001 0.02 0.10  < 0.001 0.05
ODD path (%) 7.70 7.70 0.00 0.20 4.14 1.00 0.07 0.07
CD 54.81 6.30 53.05 4.16 51.64 2.66 0.15 3.18 0.20 0.06 0.41
CD path (%) 7.70 0.00 0.00 0.04 0.94 0.07 0.07 1.00
ADHD, Attention Deficit/Hyperactivity Disorder; Aff Dis, Affective Disorder; AggBehav, Aggressive Behavior; Anx Dis, Anxiety Disorder; Anx/Dep, Anxious/
Depressed; AttProbl, Attention Problems; CD, Conduct Disorder; EmoFunct, Emotional Functioning; ExtProbl, Externalizing Problems; IE, idiopathic epiplepsy; 
IntProbl, Internalizing Problems; K-W, Kruskal-Wallis; NT1, type 1 narcolepsy; ODD, Oppositional Defiant Disorder; Path, pathological score; PhyFunct, 
Physical Functioning; PhyHSS, Physical Health Summary Score; PPR, parent-proxy report; PsyHSS, Psychosocial Health Summary Score; RBB, Rule-
Breaking Behavior; SchFunct, School Functioning; SD, standard deviation; SocFunct, Social Functioning; SocProbl, Social Problems; SomCompl, Somatic 
Complaints; Som Dis, Somatic Disorder; SR, Self-report; ThProbl, Thought Problems; TotProbl, Total Problems; With/Dep, Withdrawn/Depressed.
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scores. Neither somatic nor conduct disorder areas showed 
significant differences among groups (Figure 2).
Quality of Life
PedsQL results in NT1 patients and healthy controls are re-
ported in Table 2. NT1 patients had physical, emotional and 
social subscales and physical health summary scores compa-
rable to controls considering either self-reported or parent-
proxy report. Conversely, NT1 patients had lower school 
functioning and psychosocial health summary scores than 
controls, the latter finding exclusively according to parent-
proxy report.
Correlations of CBCL Results
The correlational analyses among CBCL results, PedsQL, and 
clinical/demographic data are reported separately in the dif-
ferent groups in Table 3 and Table 4.
In NT1 patients, social scale score was positively correlated 
with physical (parent and self-report), and social functioning 
(parent), as well as with physical health summary score (parent 
and self report), whereas school scale score positively corre-
lated only with self-reported social functioning.
No significant correlations were found in controls for the 
adaptive scales.
In NT1, physical functioning and health summary scores 
were inversely correlated with anxious/depressed and with 
somatic complaints according to parents and patients, respec-
tively. Emotional functioning was inversely correlated with 
most of the CBCL syndromes and DSM-oriented scales ac-
cording to parents, a cluster of findings confirmed by self-
reported assessment only for 
the anxiety disorder scale. 
Similarly, social and school 
functioning were inversely 
correlated with somatic, so-
cial, attention, internalizing, 
and total problem scores, 
with additional associations 
between social functioning, 
anxious/depressed, somatic, 
and CD as well as between 
school functioning, thought, 
and ADHD according to 
parent proxy-report. Pa-
tients’ self-report confirmed 
the aforementioned associa-
tions only between social and 
school functioning versus so-
matic complaints and ADHD, 
but showed an inverse cor-
relation also between social 
functioning and anxiety dis-
order. Overall, psychosocial 
health summary had a strong 
negative association with 
most CBCL results according 
to parents, a finding not mir-
rored by patients’ self-reports.
Figure 2—Distribution of T-scores  in Diagnostic and Statistical Manual 
Oriented scales. Distribution of T-scores for NT1 (gray box), IE patients 
(dark gray box), and controls (black box) in Diagnostic and Statistical 
Manual Oriented scales. In the box plot graph, box’s sides mark the 
first and third quartiles, the central line represents the median and the 
whiskers account for the maximum and minimum; outliers points lie 
outside the fences. The horizontal lines mark clinical/normal bound-
aries. ADHD, attention deficit/hyperactivity disorder; CBCL, Child 
Behavior Checklist; IE, idiopathic epilepsies; NT1, narcolepsy type 1; 
ODD, oppositional/defiant disorder.
Table 2—Scale descriptives for Pediatric Quality of Life Inventory in children with type 1 narcolepsy self-report 
and parent proxy-report and comparisons with healthy children scores.
Parent proxy-report
NT1 Controls
Mean SD Mean SD M-W test
Core Domains
Physical Functioning 593.75 201.52 678.85 80.22 0.40
Emotional Functioning 334.38 119.97 361.54 77.86 0.45
Social Functioning 419.79 74.08 442.31 51.85 0.32
School Functioning 304.17 108.01 408.65 76.14  < 0.001
Summary Scores
Physical Health Summary Score 74.22 25.19 84.99 9.92 0.38
Psychosocial Health Summary Score 70.20 16.56 80.83 10.04 0.01
Self-report
NT1 Controls
Mean SD Mean SD M-W test
Core Domains
Physical Functioning 621.88 121.43 656.00 63.44 0.48
Emotional Functioning 335.42 99.16 332.00 83.70 0.77
Social Functioning 429.17 63.70 442.00 55.77 0.55
School Functioning 318.75 93.03 375.00 82.60 0.02
Summary Scores
Physical Health Summary Score 77.58 15.05 82.00 7.94 0.45
Psychosocial Health Summary Score 71.94 12.91 76.72 10.95 0.14
MW, Mann-Whitney U tst; NT1, type 1 narcolepsy; SD, standard deviation.
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In healthy controls, CBCL and PedsQL results were not 
significantly correlated.
In NT1 patients, a longer diagnostic delay was associated 
with more somatic complaints/disorder, whereas longer dis-
ease duration was associated with fewer aggressive and exter-
nalizing problems. EDS was positively correlated with somatic, 
thought, attention problems, and ADHD. Conversely, objective 
sleep propensity at the MSLT, CSF HCRT-1, and nocturnal 
sleep features did not show significant correlations, but a nega-
tive relation between sleep efficiency and rule-breaking be-
havior. In IE patients, CBCL results were not correlated with 
clinical features.
Effect of Pharmacological Treatment
Treated NT1 patients (Table S1 in the supplemental material) 
showed lower scores than untreated patients in attention prob-
lems, particularly when treated with sodium oxybate, and in 
ADHD scale. NT1 patients receiving sodium oxybate treatment 
had significantly higher school functioning than drug-naïve 
ones, and those treated with venlafaxine showed better scores 
in Aggressive scale and ODD. Modafinil therapy did not show 
significant associations, and no differences in CBCL profile 
were observed comparing treated and untreated IE patients 
(Table S2 in the supplemental material).
DISCUSSION
We documented that young patients with NT1 had more behav-
ioral problems than IE patients and healthy controls: a higher 
incidence of anxious/depressed, withdrawn/depressed, social, 
thought, attention problems, somatic complaints, and aggres-
sive behaviors have been recorded. However, we should high-
light that NT1 patients’ mean T scores fell within the normal 
ranges on each of these summary and syndrome scales, but for 
withdrawn/depressed behavior, somatic complaints, thought 
and internalizing problems. These specific psychological 
features can be useful to better manage NT1 at a young age: 
avoidance of situations that would precipitate cataplexy or 
draw attention to sleepiness is common in patients with narco-
lepsy, but extreme withdrawal associated with thought disorder 
should suggest a depressive or even a psychotic disorder.46
Previous reports disclosed a high prevalence of anxiety 
and depressive disorders in children with narcolepsy. Dorris 
et al.34 found that children with narcolepsy presented high 
scores in internalizing problems, especially anxious/depressed 
and withdrawn/depressed behavior on the CBCL, and Stores 
et al.32 reported that children with narcolepsy scored signifi-
cantly higher than controls on the Child Depression Inventory. 
Szakács et al.35 reported that 20% of children with narcolepsy 
had a major depression, and 10% of them had a general anxiety 
Table 3A—Correlations between Child Behavioral Checklist scores and Pediatric Quality of Life Inventory scores in patients with type 1 narcolepsy.
CBCL Scales
PedsQL
PhyFunct EmoFunct SocFunct SchFunct PhyHSS PsyHSS
PPR SR PPR SR PPR SR PPR SR PPR SR PPR SR
Activities 0.40 0.02 0.00 0.08 0.06 0.26 0.13 −0.12 0.40 0.005 0.10 0.06
Social 0.43* 0.50* 0.05 0.37 0.49* 0.34 0.15 0.14 0.43* 0.50* 0.24 0.35
School 0.16 0.17 0.11 −0.08 0.32 0.41* −0.02 −0.06 0.16 0.17 0.17 0.11
Anx/Dep −0.40* −0.23 −0.62** −0.15 −0.46* −0.08 −0.37 −0.19 −0.40* −0.24 −0.66** −0.20
With/Dep −0.36 −0.19 −0.47* −0.23 −0.35 −0.05 −0.26 −0.10 −0.36 −0.20 −0.51* −0.20
SomCompl −0.26 −0.46* −0.53** −0.21 −0.58** −0.40* −0.45* −0.33 −0.26 0.47* −0.67** −0.38
SocProbl −0.22 −0.22 −0.67** −0.21 −0.58** −0.18 −0.41* −0.30 −0.22 −0.24 −0.73** −0.30
ThProbl −0.35 −0.31 −0.53** −0.23 −0.36 0.04 −0.46* −0.20 −0.35 −0.32 0.55** −0.19
AttProbl −0.23 −0.07 −0.52** −0.09 −0.45* 0.10 −0.58** −0.33 −0.23 −0.08 −0.66** −0.17
RBB 0.09 0.26 −0.13 0.21 −0.12 0.14 0.03 0.13 0.09 0.26 −0.12 0.25
AggBehav −0.34 −0.12 −0.53** 0.06 −0.39 0.19 −0.38 −0.107 −0.34 −0.12 −0.60** 0.01
IntProbl −0.39 −0.25 −0.69** −0.20 −0.51* −0.20 −0.47* −0.229 −0.39 −0.25 −0.75** −0.28
ExtProbl −0.17 0.08 −0.50* 0.06 −0.29 0.18 −0.33 −0.045 −0.17 0.07 −0.52** 0.06
TotProbl −0.27 −0.16 −0.64** −0.21 −0.42* −0.09 −0.50* −0.235 −0.27 −0.17 −0.68** −0.24
Aff Dis −0.36 −0.21 −0.44* −0.18 −0.40 0.06 −0.35 −0.23 −0.36 −0.21 −0.50* −0.18
Anx Dis −0.14 −0.23 −0.60** −0.43* −0.37 −0.53* −0.27 −0.18 −0.14 −0.25 −0.56** −0.41
Som Dis −0.16 −0.29 −0.50* −0.08 −0.62** −0.36 −0.27 −0.17 −0.16 −0.30 −0.58** −0.22
ADHD −0.30 −0.15 −0.40 −0.21 −0.40 0.20 −0.60** −0.46* −0.30 −0.16 −0.57** −0.22
ODD −0.07 0.17 −0.37 0.06 −0.40 0.13 −0.03 0.18 −0.07 0.16 −0.35 0.20
CD −0.11 0.15 −0.27 0.22 −0.42* 0.21 −0.19 0.01 −0.11 0.15 −0.40 0.19
*P < 0.05; **P < 0.001. ADHD, Attention Deficit/Hyperactivity Disorder; Aff Dis, Affective Disorder; AggBehav, Aggressive Behavior; Anx Dis, Anxiety 
Disorder; Anx/Dep, Anxious/Depressed; AttProbl, Attention Problems; CD, Conduct Disorder; EmoFunct, Emotional Functioning; ExtProbl, Externalizing 
Problems; IntProbl, Internalizing Problems; NT1, type 1 narcolepsy; ODD, Oppositional Defiant Disorder; PedsQL, Pediatric Quality of Life Inventory; 
PhyFunct, Physical Functioning; PhyHSS, Physical Health Summary Score; PPR, parent-proxy report; PsyHSS, Psychosocial Health Summary Score; 
RBB, Rule-Breaking Behavior; SchFunct, School Functioning; SocFunct, Social Functioning; SocProbl, Social Problems; SomCompl, Somatic Complaints; 
Som Dis, Somatic Disorder; SR, Self report; ThProbl, Thought Problems; TotProbl, Total Problems; With/Dep, Withdrawn/Depressed.
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disorder, while Inocente et al.33 described depressive feelings 
in up to 25% of a sample of 117 young patients with narcolepsy.
Several reports showed that adults with narcolepsy have a 
high rate of psychiatric symptoms and disorders compared to 
patients with symptomatic or idiopathic hypersomnia: mood 
disorders occur in up to 57% of patients with narcolepsy, al-
though self-reported depressive symptoms are frequently 
insufficient to satisfy the diagnostic criteria for a major depres-
sive disorder.17,47–49 Anxiety disorders, especially panic and so-
cial phobia, occur more commonly in NT1 patients than in the 
general population.17,19
Psychotic disorders have often been suspected in adult 
patients with narcolepsy, and the disease may also be misdi-
agnosed as a psychiatric disorder due to hallucinations.16,50–55 
Although psychotic symptoms in narcolepsy may reflect a 
stimulant-induced psychosis, and in these situations the psy-
chiatric symptoms resolve when medication dose is lowered, 
reports on adults and children with dual narcolepsy and schizo-
phrenia are frequent.36,56–64 Finally, the presence of hypnagogic 
hallucinations seems positively related to the development of 
psychosis in vulnerable individuals.65 ADHD symptoms are 
more prevalent in adults with narcolepsy compared to healthy 
controls, and recent data confirmed this association in children 
with narcolepsy.13,20
In our study, QoL was worse in young patients with NT1 
than in controls according to their parents, a finding partially 
confirmed by children with NT1. Previous studies investi-
gating the effect of narcolepsy on QoL showed greater impair-
ment in the mental health subscale versus controls, with no 
differences between children with narcolepsy or EDS, and 
that the domains energy/vitality and physical and psycholog-
ical well-being were mostly impaired in young patients with 
narcolepsy.32,37
In contrast with a previous study, we found significant cor-
relations between behavioral and QoL aspects, as well as with 
clinical characteristics: observation close to disease onset, 
diagnostic delay, and EDS (at PDSS) were correlated with 
behavior worsening, suggesting the importance of routinely 
assessing QoL and psychological features in young patients 
with NT1 for early detection of behavioral problems.32 These 
findings confirm the importance of both an early NT1 diag-
nosis and treatment in order to reduce the disease burden.11 In-
deed, our data indicate that pharmacological treatment, that is 
off-label in the pediatric population, was associated with better 
outcomes in some CBCL scales: sodium oxybate improved 
attention, and venlafaxine reduced aggressive and opposi-
tive-defiant behaviors. Although several studies have shown 
antiepileptic drugs effects on cognitive processes and behavior, 
Table 3B—Correlations between Child Behavioral Checklist scores and Pediatric Quality of Life Inventory scores in healthy control patients.
CBCL Scales
PedsQL
PhyFunct EmoFunct SocFunct SchFunct PhyHSS PsyHSS
PPR SR PPR SR PPR SR PPR SR PPR SR PPR SR
Activities 0.10 −0.01 −0.12 0.23 0.11 0.07 0.04 0.12 −0.26 0.27 0.043 0.15
Social 0.05 0.09 0.07 0.18 0.07 0.16 0.01 0.16 0.05 0.22 0.016 0.22
School −0.32 −0.23 −0.38 −0.04 −0.31 −0.27 −0.07 −0.18 −0.23 0.16 −0.07 −0.08
Anx/Dep 0.19 −0.07 0.07 −0.11 0.19 −0.07 0.15 −0.05 −0.02 −0.14 0.15 −0.11
With/Dep 0.29 −0.05 0.06 −0.14 0.29 −0.08 0.24 −0.04 −0.02 −0.01 0.24 −0.04
SomCompl 0.05 −0.11 0.11 −0.03 0.04 −0.03 −0.17 −0.29 −0.25 −0.25 −0.17 −0.36
SocProbl 0.12 −0.06 0.03 −0.08 0.12 −0.06 0.11 −0.05 −0.05 −0.16 0.11 −0.13
ThProbl 0.31 −0.16 −0.11 −0.01 0.31 −0.13 0.10 −0.14 −0.32 −0.06 0.10 −0.21
AttProbl 0.33 0.09 0.10 −0.06 0.33 0.05 0.17 0.04 0.02 −0.27 0.17 −0.11
RBB 0.334 −0.073 −0.14 −0.05 0.33 −0.11 0.13 −0.14 −0.26 −0.01 0.13 −0.17
AggBehav 0.09 −0.04 −0.01 −0.10 0.08 −0.08 0.11 −0.12 −0.07 0.06 0.11 −0.05
IntProbl 0.22 0.01 0.10 −0.08 0.21 0.00 0.08 −0.18 −0.12 −0.21 0.08 −0.22
ExtProbl 0.07 0.01 0.04 −0.09 0.07 −0.03 0.08 −0.18 −0.16 −0.08 0.08 −0.18
TotProbl 0.12 −0.02 0.04 −0.06 0.11 −0.03 0.03 −0.18 −0.13 −0.17 0.03 −0.21
Aff Dis 0.30 −0.07 0.03 −0.13 0.29 −0.09 0.23 −0.15 −0.19 −0.19 0.23 −0.22
Anx Dis 0.16 −0.01 0.18 −0.11 0.15 0.00 0.17 0.00 −0.18 −0.11 0.17 0.00
Som Dis −0.02 −0.03 0.18 0.13 −0.04 0.12 −0.22 −0.19 −0.09 −0.04 −0.22 −0.14
ADHD 0.10 0.04 0.28 0.09 0.09 0.16 0.00 −0.06 0.04 0.00 0.00 −0.02
ODD 0.11 0.02 0.12 0.05 0.10 0.08 0.25 0.03 0.12 0.13 0.25 0.13
CD 0.12 0.19 0.11 0.00 0.12 0.14 0.20 0.15 0.19 0.03 0.19 0.15
ADHD, Attention Deficit/Hyperactivity Disorder; Aff Dis, Affective Disorder; AggBehav, Aggressive Behavior; Anx Dis, Anxiety Disorder; Anx/Dep, Anxious/
Depressed; AttProbl, Attention Problems; CD, Conduct Disorder; EmoFunct, Emotional Functioning; ExtProbl, Externalizing Problems; IntProbl, Internalizing 
Problems; ODD, Oppositional Defiant Disorder; PedsQL, Pediatric Quality of Life Inventory; PhyFunct, Physical Functioning; PhyHSS, Physical Health 
Summary Score; PPR, parent-proxy report; PsyHSS, Psychosocial Health Summary Score; RBB, Rule-Breaking Behavior; SchFunct, School Functioning; 
SocFunct, Social Functioning; SocProbl, Social Problems; SomCompl, Somatic Complaints; Som Dis, Somatic Disorder; SR, Self report; ThProbl, Thought 
Problems; TotProbl, Total Problems; With/Dep, Withdrawn/Depressed.
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Table 4A—Correlations between Child Behavioral Checklist scores and clinical correlates in patients with type 1 narcolepsy.
CBCL Scales AOb AO AD DDe DDu SY PDSS hcrt
MSLT Daytime NAPs PSG second night
SOREMPs SL n TST SL REML TST SE WASO
Activities 0.18 0.09 0.12 0.03 0.18 0.08 −0.25 −0.05 0.07 0.22 −0.04 −0.05 0.32 0.04 −0.03 −0.32 0.47*
Social 0.01 0.22 0.21 −0.02 −0.03 0.09 −0.29 0.32 0.05 0.28 −0.34 −0.10 0.22 −0.26 −0.21 −0.18 0.11
School 0.09 0.37* 0.09 −0.30 −0.05 0.16 −0.11 0.08 −0.11 0.36 0.15 0.34 0.13 0.04 −0.16 0.11 −0.29
Anx/Dep −0.19 −0.08 −0.10 −0.04 −0.27 −0.20 0.14 −0.33 0.13 0.08 −0.06 −0.06 −0.30 0.12 −0.03 −0.25 0.41
With/Dep −0.28 −0.24 −0.34 −0.13 −0.23 −0.19 0.02 −0.14 0.24 0.07 0.07 −0.10 −0.26 0.23 −0.03 −0.13 0.24
Som Compl 0.08 −0.14 0.26 0.45* 0.04 0.05 0.45* 0.01 −0.20 −0.22 −0.08 −0.12 0.03 0.28 −0.07 −0.10 0.24
Soc Probl −0.05 0.01 0.02 0.02 −0.21 −0.09 0.26 −0.03 0.16 −0.02 −0.11 −0.09 −0.04 0.12 −0.17 −0.03 0.13
Th Probl −0.18 −0.04 −0.07 −0.04 −0.21 −0.19 0.40* −0.05 −0.11 −0.05 0.17 0.16 0.13 0.28 −0.08 −0.02 0.08
Att Probl −0.07 0.07 0.16 0.11 −0.28 −0.22 0.39* −0.05 0.15 0.03 −0.24 −0.28 0.02 0.26 0.07 −0.21 0.39
RBB −0.32 −0.17 −0.22 −0.06 −0.22 −0.28 0.00 −0.31 0.15 0.24 −0.26 −0.15 −0.06 −0.12 0.19 −0.47* 0.55**
Agg Behav −0.28 −0.06 −0.08 −0.02 −0.40* −0.29 0.28 −0.04 0.23 0.16 −0.28 −0.20 −0.26 0.14 −0.01 −0.25 0.46*
Int Probl −0.23 −0.22 −0.13 0.09 −0.22 −0.20 0.22 −0.10 0.10 0.02 −0.07 −0.20 −0.17 0.25 −0.05 −0.18 0.34
Ext Probl −0.36 −0.03 −0.15 −0.14 −0.44* −0.35 0.18 −0.06 0.18 0.23 −0.30 −0.20 −0.19 0.03 0.07 −0.34 0.45*
Tot Probl −0.23 −0.02 −0.04 −0.03 −0.34 −0.24 0.30 −0.10 0.04 0.14 −0.12 −0.20 −0.08 0.17 0.07 −0.26 0.38
Aff Dis −0.35 −0.19 −0.33 −0.17 −0.33 −0.29 0.23 −0.20 −0.02 0.07 0.16 0.09 −0.09 −0.19 0.00 −0.02 0.22
Anx Dis −0.14 0.07 −0.05 −0.15 −0.25 −0.09 0.19 −0.36 0.08 0.07 0.08 0.05 −0.16 0.10 −0.15 −0.17 0.40
Som Dis 0.17 −0.13 0.29 0.48* 0.07 0.13 0.34 0.16 −0.23 −0.28 −0.18 −0.08 −0.03 0.05 −0.09 0.27 −0.15
ADHD −0.01 0.21 0.25 0.05 −0.33 −0.07 0.47* −0.30 −0.09 0.16 −0.10 −0.10 −0.09 0.21 0.11 −0.11 0.39
ODD −0.09 −0.04 0.01 0.06 −0.16 −0.08 0.27 −0.06 0.27 0.22 −0.15 −0.14 0.05 −0.09 −0.24 0.18 −0.11
CD −0.26 −0.21 −0.16 0.05 −0.27 −0.30 0.26 −0.09 0.13 0.18 −0.34 −0.10 −0.12 −0.13 0.03 0.02 0.14
*P < 0.05 ; **P < 0.001. AD, age at diagnosis; ADHD, Attention Deficit/Hyperactivity Disorder; Aff Dis, Affective Disorder; Agg Behav, Aggressive Behavior; 
Anx Dis, Anxiety Disorder; Anx/Dep, Anxious/Depressed; AO, age of onset; AOb, age at observation; Att Probl, Attention Problems; CD, Conduct Disorder; 
DDe, diagnostic delay; DDu, disease duration; Ext Probl, Externalizing Problems; hcrt, hypocretin 1 levels; Int Probl, Internalizing Problems; MSLT, Multiple 
Sleep Latency Test; NAPs, daytime naps; ODD, Oppositional Defiant Disorder; PDSS, Pediatric Daytime Sleepiness Scale; PSG, polysomnography; 
REML2n, REM latency second night; RBB, Rule-Breaking Behavior; SE, sleep efficiency; SL, sleep latency; SocProbl, Social Problems; SomCompl, Somatic 
Complaints; Som Dis, Somatic Disorder; SOREMPs, sleep onset rapid eye movement periods; SY, schooling years; ThProbl, Thought Problems; Tot 
Probl, Total Problems; TST, total sleep time; WASO, wake after sleep onset; With/Dep, Withdrawn/Depressed.
Table 4B—Correlations of Child Behavioral Checklist scores and clinical correlates in patients with idiopathic epilepsy.
CBCL Scales
Age at 
Observation
Age of
Onset
Age at 
Diagnosis
Diagnostic 
Delay
Disease 
Duration
Schooling
Years
Activities −0.02 0.17 0.17 1.00 −0.12 −0.01
Social −0.30 0.34* 0.34* 1.00 −0.45** −0.29
School −0.05 0.45** 0.45** 1.00 −0.32* −0.06
Anxious/Depressed −0.01 −0.03 −0.03 1.00 0.01 −0.02
Withdrawn/Depressed −0.10 0.18 0.18 1.00 −0.19 −0.10
Somatic Complaints −0.16 −0.04 −0.04 1.00 −0.10 −0.15
Social Problems 0.12 0.00 0.00 1.00 0.09 0.13
Thought Problems −0.09 0.06 0.06 1.00 −0.11 −0.09
Attention Problems 0.02 −0.04 −0.04 1.00 0.04 0.01
Rule-Breaking Behavior 0.18 −0.15 −0.15 1.00 0.24 0.19
Aggressive Behavior 0.05 −0.01 −0.01 1.00 0.04 0.04
Internalizing Problems 0.04 0.03 0.03 1.00 0.01 0.03
Externalizing Problems 0.13 0.06 0.06 1.00 0.07 0.14
Total Problems 0.11 0.03 0.03 1.00 0.06 0.11
Affective Disorder −0.04 0.14 0.14 1.00 −0.11 −0.02
Anxiety Disorder −0.06 0.01 0.01 1.00 −0.05 −0.07
Somatic Disorder −0.10 0.00 0.00 1.00 −0.08 −0.10
Attention Deficit/Hyperactivity Disorder 0.08 0.02 0.02 1.00 0.05 0.07
Oppositional Defiant Disorder 0.10 0.08 0.08 1.00 0.03 0.11
Conduct Disorder 0.00 −0.07 −0.07 1.00 0.04 0.00
*P < 0.05 ; **P < 0.001. CBCL, Child Behavioral Checklist.
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we did not observe significant differences in CBCL scores be-
tween treated and untreated IE patients, probably due to the 
small number of patients involved.66 Conversely, our study 
disclosed statistically significant differences between treated 
and untreated NT1 patients thus suggesting a stronger effect of 
symptomatic treatment in NT1 versus IE patients.
Chronic disorders are associated with increased risk of psy-
chiatric comorbidity with high levels of internalizing disor-
ders disclosed by the CBCL: a recent meta-analysis showed 
that externalizing problems are both illness-specific and often 
associated with impaired brain function, as in epilepsy and in 
migraine/headache.67 Therefore, the psychopathological pro-
file of childhood NT1 is similar to other chronic diseases for 
anxiety-depressive aspects, somatic complaints, and thought 
and attention problems, but it is peculiar for aspects of with-
drawn/depression, social problems, and aggressive behavior. 
Further studies are needed to address the correlations among 
NT1 specific psychological traits, EDS, and emotions given 
the recently discovered role of hypocretinergic transmission 
during proactive behavior, and the intrinsic link between posi-
tive emotions and cataplexy.68,69
We acknowledge that our study has limitations. First, the 
cross-sectional design cannot demonstrate causation, but 
only compare findings in NT1 versus controls and IE patients. 
Second, the absence of sleep parameters in the IE and control 
group limits the comparison with those obtained in NT1 chil-
dren to disentangle the potential relationship between behav-
ioral and sleep patterns. Third, we used the parent version of 
CBCL, and parallel information from the children themselves 
and/or data from behavioral observation would strengthen 
the current findings. Acknowledging that the CBCL includes 
some items concerning sleep, we also calculated the results ex-
cluding ambiguous items without obtaining different findings 
(data not shown), thus confirming the high internal consistency 
of the CBCL itself. Finally, the CBCL is a screening tool that 
does not allow discrete psychiatric diagnosis.
CONCLUSIONS
Children suffering from NT1 had a high representation of in-
ternalizing problems, especially depressed-anxious, aspects 
of withdrawal, somatic complaints, and thought disorders that 
may be common in chronic diseases. Conversely, the presence 
of externalizing problems, such as attention problems and ag-
gressive behavior, counted as anecdotal and confirmed in our 
study, should be considered as part of the spectrum of the NT1 
behavioral phenotype.
Future interventional-longitudinal studies are needed to 
characterize the behavioral evolution, to assess the effect of 
risk factors for the development of psychiatric disorders, and 
to evaluate the effectiveness of NT1 pharmacological and/or 
psychological treatments.
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